1/11/2013

An FDA panel recommended the approval of Johnson & Johnson's Invokana, or canagliflozin to treat type 2 diabetes in a 10-5 vote. Some advisers suggested that patients with impaired kidneys should be told not to take the drug.

Related Summaries